Regencell Bioscience Holdings Ltd (RGC) stock
RGCNasdaqMedicinal Chemicals & Botanical Products
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.55−0.17 (-3.60%)
Close on Nov 17, 2026Market cap $2.26BP/E –Yield –
Regencell Bioscience EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$2.37. The highest annual figure on record is -$0.00 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$2.37 | – |
| FY2025 | Jun 30, 2025 | -$0.72 | – |
| FY2024 | Jun 30, 2024 | -$0.87 | – |
| FY2023 | Jun 30, 2023 | -$1.19 | – |
| FY2022 | Jun 30, 2022 | -$0.02 | – |
| FY2021 | Jun 30, 2021 | -$0.00 | – |
| FY2020 | Jun 30, 2020 | -$0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?